Fresh analysis reveals that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who end conventional lifestyle plans.
Published data in a major health publication points out that while overweight people can lose a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"Users buying these treatments need to be cognizant of the danger of quick rebound weight gain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
This pace of regain suggests a reversion to pre-treatment weight within about 18 months.
Comparing Treatments
The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers note that people who lose weight through dieting typically have a more gradual creep back—around 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Doctors suggest the mechanism of the injections is key to understanding the accelerated regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls hunger.
"Sustained high doses of GLP-1 levels far above than normal could lead to the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating far more likely."
A Chronic Issue?
Health authorities recommend the jabs for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts contend that, considering the likelihood of weight regain, the therapy is often long-term.
This opinion is supported by pharmaceutical companies, who state that the results "underscore the chronic nature of excess weight," akin to managing conditions like high blood pressure.
Patient Testimonies
Users who have discontinued the jabs report a sudden return of cravings.
"I experienced a trigger that goes on and you're instantly starving," recalled a patient.
This difficulty is compounded if patients have not adopted lasting lifestyle or habit changes during therapy.
Growing Adoption
Figures indicate that a significant number of people in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Adoption is greater among females than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, clinicians caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on integrated lifestyle support.
